Clinical Trials
9 trialsNCT02562365 2022-07-27
ACTS
Fudan University
Phase 2 Unknown
NCT05422183 2022-06-16
Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer
Zhongda Hospital
Phase 2 Unknown
NCT02639650 2022-06-03
Study of Paclitaxel Plus Cisplatin as the First-line Chemotherapy in High Risk Gestational Trophoblastic Tumor
Women's Hospital School Of Medicine Zhejiang University
Phase 3 Unknown
NCT04217798 2021-09-01
Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian Cancer
Peking Union Medical College Hospital
Phase 2 Unknown
NCT04383977 2020-05-12
Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant Ovarian Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Unknown
NCT04000295 2019-10-08
Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant Ovarian Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT03298074 2017-09-29
Apatinib Plus Etoposide Versus Etoposide Alone for Platinum-resistant Recurrent Ovarian Cancer
Guangxi Medical University
Phase 2 Unknown
NCT00274950 2013-09-17
Observation and/or Combination Chemotherapy After Surgery or Biopsy in Treating Young Patients With Extracranial Germ Cell Tumors
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00276718 2013-09-17
Etoposide, Carboplatin, and Bleomycin in Treating Young Patients Undergoing Surgery For Malignant Germ Cell Tumors
National Cancer Institute (NCI)
Phase NA Unknown